A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
Titel:
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
Auteur:
Kindler, H.L. Richards, D.A. Garbo, L.E. Garon, E.B. Stephenson Jr., J.J. Rocha-Lima, C.M. Safran, H. Chan, D. Kocs, D.M. Galimi, F. McGreivy, J. Bray, S.L. Hei, Y. Feigal, E.G. Loh, E. Fuchs, C.S.